13F filer · CIK 1617201
Prosight Management, LP
DALLAS, TX · filing since Q4 2017 · last filing Aug 14, 2026
Reported value
$580.4M
$-29.5M vs prior
Positions
36
New / sold out
5 / 15
Added / reduced
16 / 15
Turnover
27.8%
buys $165.4M · sells $194.9M
Top-10 weight
70.7%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | INSMED INC | +375,609 | – | +$40.0M |
| Added | BOSTON SCIENTIFIC CORP | +474,726 | +59.7% | +$20.3M |
| Added | IRHYTHM HOLDINGS INC | +155,500 | +1555.0% | +$18.5M |
| Added | LAKEFRONT BIOTHERAPEUTICS NV | +493,344 | +31.8% | +$14.8M |
| New | MINERALYS THERAPEUTICS INC | +449,795 | – | +$12.1M |
| Added | SYNDAX PHARMACEUTICALS INC | +430,000 | +55.8% | +$9.4M |
| Added | ALNYLAM PHARMACEUTICALS INC | +22,080 | +29.1% | +$6.6M |
| Added | SHATTUCK LABS INC | +953,438 | +19.1% | +$6.6M |
| New | OPTION CARE HEALTH INC | +270,716 | – | +$5.7M |
| Added | NEKTAR THERAPEUTICS | +75,000 | +10.2% | +$5.2M |
11 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | PROCEPT BIOROBOTICS CORP | -1,676,731 | -86.2% | $-37.9M |
| Reduced | MEIRAGTX HLDGS PLC | -2,539,971 | -96.6% | $-34.3M |
| Reduced | GENEDX HOLDINGS CORP | -437,963 | -83.7% | $-30.1M |
| Reduced | KURA ONCOLOGY INC | -1,334,736 | -39.8% | $-14.6M |
| Sold out | CONCENTRA GROUP HOLDINGS PAR | -505,822 | -100.0% | $-10.8M |
| Sold out | TERNS PHARMACEUTICALS INC | -202,300 | -100.0% | $-10.7M |
| Sold out | PHREESIA INC | -1,100,000 | -100.0% | $-9.2M |
| Reduced | ALKERMES PLC | -119,243 | -23.2% | $-6.2M |
| Sold out | SCHRODINGER INC | -510,578 | -100.0% | $-5.8M |
| Reduced | ONKURE THERAPEUTICS INC | -1,175,389 | -54.6% | $-5.4M |
20 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | LAKEFRONT BIOTHERAPEUTICS NVSPON ADR | 2,043,344 | $61.3M | 10.56% |
| 2 | JANUX THERAPEUTICS INCCOM | 3,804,481 | $58.4M | 10.07% |
| 3 | NEKTAR THERAPEUTICSCOM NEW | 810,000 | $56.5M | 9.74% |
| 4 | BOSTON SCIENTIFIC CORPCOM | 1,270,273 | $54.2M | 9.34% |
| 5 | SHATTUCK LABS INCCOM | 5,957,877 | $41.3M | 7.12% |
| 6 | INSMED INCCOM PAR $.01 | 375,609 | $40.0M | 6.90% |
| 7 | ALNYLAM PHARMACEUTICALS INCCOM | 98,080 | $29.5M | 5.09% |
| 8 | SYNDAX PHARMACEUTICALS INCCOM | 1,200,000 | $26.2M | 4.52% |
| 9 | KURA ONCOLOGY INCCOM | 2,021,964 | $22.2M | 3.82% |
| 10 | ALKERMES PLCSHS | 394,389 | $20.7M | 3.56% |
26 more rows. Subscribe for $29/month to see every row, download the data and use the API.